Curative Biotechnology (OTCMKTS:CUBTD – Get Free Report) and Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Curative Biotechnology and Zentalis Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curative Biotechnology | N/A | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals | $67.43 million | 4.37 | -$137.06 million | ($1.73) | -2.39 |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Curative Biotechnology and Zentalis Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curative Biotechnology | 0 | 0 | 0 | 0 | 0.00 |
| Zentalis Pharmaceuticals | 1 | 4 | 1 | 1 | 2.29 |
Zentalis Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 20.77%. Given Zentalis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Curative Biotechnology.
Profitability
This table compares Curative Biotechnology and Zentalis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curative Biotechnology | N/A | N/A | N/A |
| Zentalis Pharmaceuticals | N/A | -53.61% | -40.67% |
Risk and Volatility
Curative Biotechnology has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
Summary
Zentalis Pharmaceuticals beats Curative Biotechnology on 6 of the 8 factors compared between the two stocks.
About Curative Biotechnology
Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for Curative Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curative Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
